You're a mid-size specialty pharma company in growth mode. Eight months ago you had 40 reps. Now you have 80. In 12 months, you'll have 150. Your hiring pipeline is strong. Your portfolio is expanding. Your revenue is growing.

Your training is a mess.

You started with one person handling training. That person built the initial curriculum for your 40 reps. Now you have 80 reps with the same training infrastructure. Your hiring is adding 5-6 reps per month and that person is drowning.

You keep saying you'll "get training figured out" when things stabilize. But things don't stabilize in growth mode. You keep hiring. You keep launching. You keep expanding.

Training gets treated as an afterthought because you're focused on growth.

That's the mistake that costs you 20-30% of your potential revenue.

Why Specialty Pharma Growth Is Different

Specialty pharma's growth creates different training challenges than traditional pharma:

1. You can't afford ramp time waste. In traditional pharma, reps might take 12-16 weeks to hit quota. That's acceptable because you have a big portfolio and market share to protect. In specialty pharma, you're fighting for share in a smaller market. You need reps hitting quota in 8-10 weeks. Every week of ramp time waste is revenue you won't recover.
2. Your reps are specialized, not generalists. Your reps sell deep into specific indications. They need clinical depth that generic training doesn't provide. But you don't have time to train people individually because you're scaling fast.
3. You're hiring experienced reps, not developing them. You're poaching people from larger companies, recruiting from biotech, hiring physicians who want to leave practice. These people come with entrenched selling approaches. They don't automatically adapt to your product or approach.
4. Your manager layer is thin. You probably have 2-3 managers for 80 reps. They're overloaded. If coaching is ineffective, you have no buffer. Field performance depends entirely on what your few managers can coach.

The Hidden Cost at Each Growth Stage

The cost of not building training infrastructure compounds as you scale:

Stage 1: 40 reps (Your current state)

You have one person handling training. They're busy but managing. Reps are ramping in 10-12 weeks. You're hitting 70% of quota in month three. It's workable.

Cost of poor training: 10% of potential revenue. Maybe $2-3M.

Stage 2: 80 reps (6 months)

Your training person can't keep up. You're still running the same basic curriculum from stage 1, just with more people. Reps are ramping slower because coaching is inconsistent. New hires aren't getting adequate attention.

You're hitting 60% of quota in month three instead of 70%. That's 15% of your expected growth revenue lost.

Cost of poor training: 15% of potential revenue. Maybe $5-7M.

Stage 3: 120 reps (12 months)

You hired a second training person, but they're both overwhelmed. You haven't updated your curriculum in six months. You're running parallel training systems because your platform can't scale. Managers are frustrated because they have no visibility into rep competency.

You're hitting 50% of quota in month three. Your best reps are carrying the load. Your middle tier is struggling. New hires are hitting quota in month 5-6 instead of month 3.

Cost of poor training: 25% of potential revenue. Maybe $12-15M.

Stage 4: 150+ reps (18 months)

You've invested in infrastructure, but you're 18 months behind where you should be. You're now building systems you should have built at stage 1. Your reps are paying the cost of infrastructure choices you made when you were small.

Cost of poor training: 20% of potential revenue. Maybe $18-22M.

What Good Enough Looks Like at Each Stage

You don't need perfect training at each stage. You need "good enough for your stage."

Stage 1: 40 reps

Good enough means:

• One training person who can handle onboarding and ongoing manager support.
• Core curriculum built for your portfolio (product knowledge, selling skills, territory strategy).
• Manager coaching that's regular and structured (monthly minimum).
• Clear certification before reps call on a physician.

Cost: One training person + platform license. Maybe $150-200K.

Stage 2: 80 reps

Good enough means:

• One training person + one training contractor or part-time person.
• Curriculum organized into core modules with segment-specific paths.
• Platform that manages parallel cohorts without manual work.
• Manager coaching structure that's scalable (playbooks, not ad-hoc).

Cost: Two training people + platform + contractors. Maybe $300-400K.

Stage 3: 120 reps

Good enough means:

• Two training people (one manager, one content developer).
• Curriculum system that's scalable (you can add products without rebuilding).
• Platform with coaching tools that make manager time more efficient.
• Clear performance metrics (ramp time, quota attainment, certification pass rates).

Cost: Two training people + infrastructure. Maybe $500-600K.

Stage 4: 150+ reps

Good enough means:

• Formal training organization (training manager, curriculum developer, platform manager).
• Sophisticated curriculum and certification systems.
• Advanced coaching analytics and playbooks.
• Ongoing training and development for veteran reps.

Cost: Three training people + infrastructure. Maybe $700-900K.

The Mistake That Costs You Most

The biggest mistake specialty pharma makes is waiting until stage 3 to build proper training infrastructure. By then, you've lost 18-24 months of potential revenue.

You don't need stage 4 infrastructure at stage 1. But you need to plan for progression. Build stage 1 infrastructure that can scale to stage 2 without major rebuild. Choose platforms that can grow with you. Train managers to coach consistently from the beginning.

If you do this, you stay ahead of the growth curve. If you don't, you're always 12-18 months behind.

Where to Invest

In growth mode, every dollar is precious. Where should you invest in training?

Priority 1: Manager coaching discipline (Highest ROI)

This is your highest-return investment. Good manager coaching can compensate for imperfect curriculum. Bad manager coaching can undermine perfect curriculum.

Invest in:

• Training your managers to coach.
• Creating coaching playbooks.
• Building visibility into where coaching is needed.

Cost: ~$50-75K per stage. Return: 20-30% improvement in rep productivity.

Priority 2: Structured onboarding (High ROI)

Compress ramp time by 2-3 weeks and you recoup your investment in onboarding efficiency in the first cohort.

Invest in:

• Clear curriculum for new hires.
• Certification that actually measures competency.
• Field ride-outs with structured feedback.

Cost: ~$100-150K per stage. Return: 15-25% faster ramp time.

Priority 3: Manager and coaching training systems (High ROI)

Your managers are your multiplier. If they coach effectively, reps perform. If they don't, reps don't.

Invest in:

• Training your managers on coaching.
• Creating structured coaching approaches.
• Measuring coaching frequency and quality.

Cost: ~$75-100K per stage. Return: 10-15% improvement in rep performance.

Priority 4: Training infrastructure and platform (Moderate ROI)

You need this eventually, but it's lower priority than coaching and onboarding.

Invest in:

• Platform that grows with you.
• Curriculum management system.
• Performance analytics.

Cost: ~$200-300K per stage. Return: 5-10% efficiency gain + foundation for future growth.

Where to Start

If you're a specialty pharma company in growth mode:

• This quarter: Build your core curriculum. Map what reps need to know to sell effectively. Don't try to be comprehensive. Build focused curriculum.
• Next quarter: Train your managers. They're your force multiplier. Invest in coaching discipline and accountability.
• Quarter 3: Implement structured onboarding. Get your next cohort of hires through formal certification.
• Quarter 4: Evaluate platform and infrastructure needs for next stage of growth.

By the end of the year, you'll have stage 1 infrastructure built. You'll be set up to scale effectively through stage 2.

The companies winning specialty pharma growth are the ones that treat training as a strategic investment in stage 1, not an afterthought they address in stage 3.